+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Glaucoma - Global Drug Forecast and Market Analysis to 2030

  • ID: 5553616
  • Report
  • January 2022
  • Region: Global
  • 160 Pages
  • GlobalData
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

FEATURED COMPANIES

  • Aerie Pharmaceuticals
  • Bausch & Lamb
  • Eisai Co Ltd
  • Nic0x
  • Ono Pharmaceutical
  • Sandoz International
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Glaucoma is the leading cause of irreversible vision loss, worldwide. The term glaucoma includes many different diseases, which are associated with differing risk factors, symptoms, treatment, and prognosis. All forms of glaucoma are characterized by the loss of the retinal ganglion cells (RGCs) and their axons that make up the optic nerve, which results in a cupping of the optic nerve head. This leads to optic nerve damage and visual field loss. Raised intraocular pressure (IOP) is the primary risk factor for glaucoma, and progression of disease will normally stop if the IOP is lowered by 30-50%. Consequently, treatment options for glaucoma are developed around lowering the IOP. Although it is possible to slow the progression of glaucoma using current treatment options, it is not possible to reverse vision loss that has resulted from the disease.

Most drugs prescribed for glaucoma can be placed into one of five drug classes. Prostaglandin analogues (PGAs) are generally used as a first-line treatment, with beta blockers (BBs), alpha adrenergic receptor agonists (AAs), carbonic anhydrase inhibitors (CAIs), and rho kinase inhibitors (RKIs) also frequently used, albeit generally as second-line therapies in combination with PGAs. PGAs can also be reformulated in sustained-release implants as opposed to topical treatments, and this is shown as a separate class within the forecast. Certain combinations of available drugs are marketed as part of fixed-dose combination (FDC) therapies. Cholinergic agonists, and alpha-adrenergic antagonists (AAA) can also be used for the treatment of glaucoma, although they are much less commonly prescribed compared with PGAs, BBs, AAs, CAIs, and RKIs. During the forecast period, several new classes of drug are expected to become available throughout the 7MM, including small interfering RNA and LRRK2 inhibitors providing ophthalmologists further options to help lower IOP.

Key Highlights

  • During the 10-year forecast period, there are seven major pipeline products that are on track to launch, driving a total forecast growth of $657.8M in the 7MM by 2030.
  • The glaucoma market is expected to grow from $2.85B in 2020 to $3.48B in 2030, a CAGR of 2%. The US is the biggest market of the 7MM, accounting for 75.0% market share in 2020. This is set to increase to 80.2% by 2030.

Key Questions Answered
  • How will the glaucoma market landscape in the 7MM (US, France, Germany, Italy, Spain, UK, Japan) change from 2020-2030?
  • What are the most promising late-stage pipeline products for glaucoma?
  • How do the clinical and commercial attributes of late-stage pipeline products compare with one another, and against existing glaucoma treatment options?
  • What are the remaining unmet needs in glaucoma therapeutics?
  • What drivers and barriers will affect glaucoma therapy sales in the 7MM over the forecast period?

Scope

  • Overview of glaucoma, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and current management strategies.
  • Topline glaucoma therapeutic market revenue from 2020-2030. Annual cost of therapy and major pipeline product sales in this forecast period are included.
  • Key topics covered include current glaucoma therapies, unmet needs and opportunities, and the drivers and barriers affecting treatment sales in the 7MM.
  • Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and detailed analysis of late-stage pipeline products.
  • Analysis of the current and future market competition in the global glaucoma therapeutic market. Insightful review of the key industry drivers, constraints, and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to Buy


The report will enable you to:

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the global sepsis therapeutic market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the sepsis therapeutic market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Aerie Pharmaceuticals
  • Bausch & Lamb
  • Eisai Co Ltd
  • Nic0x
  • Ono Pharmaceutical
  • Sandoz International

1 Glaucoma: Executive Summary
1.1 Growth Is Projected for the Glaucoma Market between 2020 and 2030
1.2 The Development of Drugs with Novel MOA or Administration Marks a Shift in Glaucoma Corporate Strategy
1.3 Some Unmet Needs Remains for Glaucoma, Particularly Improving Patient Compliance
1.4 Opportunities Remain for Products that Further Address Unmet Needs in the Glaucoma Market
1.5 Late-Stage Pipeline Drugs Entering the Glaucoma Market Are Poised to Drive Growth
1.6 What Do Physicians Think?
2 Introduction
2.1 Catalyst
2.2 Related Reports
2.3 Upcoming Reports
3 Disease Overview
3.1 Etiology and Pathophysiology
3.1.1 Overview
3.1.2 Etiology
3.1.3 Pathophysiology
3.2 Classification or Staging Systems
4 Epidemiology
4.1 Disease Background
4.2 Risk Factors and Comorbidities
4.3 Global and Historical Trends
4.4 Forecast Methodology
4.4.1 Sources Used
4.4.2 Forecast Assumptions and Methods
4.4.3 Total Prevalent Cases of POAG
4.4.4 Total Prevalent Cases of PACG
4.4.5 Total Prevalent Cases of NTG and PPG
4.4.6 Total Prevalent Cases of SG
4.4.7 Diagnosed Prevalent Cases
4.4.8 Diagnosed Incident Cases of Acute PACG
4.5 Epidemiological Forecast for Glaucoma (2020-2030)
4.5.1 Total Prevalent Cases of POAG
4.5.2 Age-Specific Total Prevalent Cases of POAG
4.5.3 Sex-Specific Total Prevalent Cases of POAG
4.5.4 Total prevalent Cases of PACG
4.5.5 Age-Specific Total Prevalent Cases of PACG
4.5.6 Sex-Specific Total Prevalent Cases of PACG
4.5.7 Total Prevalent Cases of NTG
4.5.8 Total Prevalent Cases of SG
4.5.9 Total Prevalent Cases of PPG
4.5.10 Diagnosed Prevalent Cases of POAG
4.5.11 Diagnosed Prevalent Cases of PACG
4.5.12 Diagnosed Prevalent Cases of Acute and Chronic PACG
4.5.13 Diagnosed Incident Cases of Acute PACG
4.5.14 Diagnosed Prevalent Cases of NTG
4.5.15 Diagnosed Prevalent Cases of SG
4.5.16 Diagnosed Prevalent Cases of PPG
4.6 Discussion
4.6.1 Epidemiological Forecast Insight
4.6.2 COVID-19 Impact
4.6.3 Limitations of the Analysis
4.6.4 Strengths of the Analysis
5 Disease Management
5.1 Diagnosis Overview
5.1.1 Ophthalmoscopy
5.1.2 Tonometry
5.1.3 Perimetry
5.1.4 Pachymetry
5.1.5 Gonioscopy
5.2 Treatment Overview
5.2.1 Treatment Guidelines
5.2.2 Leading Prescribed Drugs
5.2.3 Clinical Practice
5.3 US
5.4 5EU
5.5 Japan
5.6 KOL Insights on Disease Management
6 Competitive Assessment
6.1 Overview
7 Unmet Needs and Opportunity Assessment
7.1 Overview
7.2 Improved Patient Compliance
7.2.1 Unmet Need
7.2.2 Gap Analysis
7.2.3 Opportunity
7.3 Treatment Options with Greater IOP-Lowering Ability
7.3.1 Unmet Need
7.3.2 Gap Analysis
7.3.3 Opportunity
7.4 Neuroprotective Drugs
7.4.1 Unmet Need
7.4.2 Gap Analysis
7.4.3 Opportunity
7.5 Improved Diagnosis and Monitoring
7.5.1 Unmet Need
7.5.2 Gap Analysis
7.5.3 Opportunity
8 R&D Strategies
8.1 Overview
8.1.1 New IOP-Lowering Drugs
8.1.2 Sustained-Release Implants
9 Pipeline Assessment
9.1 Overview
9.2 Promising Drugs in Clinical Development
10 Pipeline Valuation Analysis
10.1 Overview
10.2 Competitive Assessment
11 Current and Future Players
11.1 Overview
11.2 Deal-Making Trends
12 Market Outlook13 Appendix
List of Tables
Table 1: Glaucoma: Key Metrics in the 7MM
Table 2: The Different Causes of Secondary Glaucoma
Table 3: Classification of Glaucoma by ICD-10 Codes
Table 4: Classification of Glaucoma by Primary and Secondary Groups
Table 5: Classification of Glaucoma by OAG and ACG Sub-types
Table 6: Risk Factors and Comorbidities for Glaucoma
Table 7: Diagnostic Tests for Glaucoma
Table 8: Ophthalmologic Imaging Techniques
Table 9: Drug Classes Used to Treat Glaucoma
Table 10: Treatment Guidelines for Glaucoma
Table 11: Most-Prescribed Drugs for Glaucoma by Class in the 7MM, 2020
Table 12: Country Profile - US
Table 13: Country Profile - 5EU
Table 14: Country Profile - Japan
Table 15: Promising Products in Late-Stage Clinical Development for Treatment of Glaucoma
Table 16: Key Deals in the Glaucoma Market, 2016-2021
Table 17: Glaucoma Market - Global Drivers and Barriers, 2020-2030
Table 18: Key Events Impacting Sales for Glaucoma in the US, 2020-2030
Table 19: Glaucoma Market - Drivers and Barriers in the US, 2020-2030
Table 20: Key Events Impacting Sales for Glaucoma in the 5EU, 2020-2030
Table 21: Glaucoma Market - Drivers and Barriers in the 5EU, 2020-2030
Table 22: Key Events Impacting Sales for Glaucoma in Japan, 2020-2030
Table 23: Glaucoma Market - Drivers and Barriers in Japan, 2020-2030
Table 24: Projected Launch Dates for Glaucoma
Table 25: Key Historical and Projected Patent Expiry Dates for Glaucoma
Table 26: High-Prescribing Physicians (non-KOLs) Surveyed, By Country
List of Figures
Figure 1: Global Sales Forecast by Country for Glaucoma in 2020 and 2030
Figure 2: Analysis of the Company Portfolio Gap in Glaucoma During the Forecast Period
Figure 3: Competitive Assessment of the Late-Stage Pipeline Agents that the Analyst Expects to Be Licensed for the Treatment of Glaucoma During the Forecast Period
Figure 4: The Aqueous Humor Flow in OAG and ACG
Figure 5: The Aqueous Humor Cycle
Figure 6: 7MM, Total Prevalence of POAG, All Ages, Men and Women, Ages =40 Years, 2020
Figure 7: 7MM, Total Prevalence of PACG, All Ages, Men and Women, Ages =40 Years, 2020
Figure 8: 7MM, Sources Used and Not Used for Total Prevalent Cases of POAG
Figure 9: 7MM, Sources Used for Total Prevalent Cases of PACG
Figure 10: 7MM, Sources Used for Total and Diagnosed Prevalent Cases of NTG
Figure 11: 7MM, Sources Used for Total Prevalent Cases of PPG
Figure 12: 7MM, Sources Used for Total and Diagnosed Prevalent Cases of SG
Figure 13: 7MM, Sources Used for Diagnosed Prevalent Cases of POAG
Figure 14: 7MM, Sources Used for Diagnosed Prevalent Case of PACG
Figure 15: 7MM, Sources Used for Diagnosed Incident Cases of Acute PACG
Figure 16: 7MM, Total prevalent Cases of POAG, Men and Women, Ages =40 Years, N, 2020
Figure 17: 7MM, Age-Specific Total Prevalent Cases of POAG, Men and Women, N, 2020
Figure 18: 7MM, Sex-Specific Total prevalent Cases of POAG, Ages =40 Years, N, 2020
Figure 19: 7MM, Total prevalent Cases of PACG, Men and Women, Ages =40 Years, N, 2020
Figure 20: 7MM, Age-Specific Total Prevalent Cases of PACG, Men and Women, N, 2020
Figure 21: 7MM, Sex-Specific Total Prevalent Cases of PACG, Ages =40 Years, N, 2020
Figure 22: 7MM, Total Prevalent Cases of NTG, Men and Women, Ages =40 Years, N, 2020
Figure 23: 7MM, Total Prevalent Cases of SG, Men and Women, Ages =40 Years, N, 2020
Figure 24: 7MM, Total Prevalent Cases of PPG, Men and Women, Ages =40 Years, N, 2020
Figure 25: 7MM, Diagnosed Prevalent Cases of POAG, Men and Women, Ages =40 Years, N, 2020
Figure 26: 7MM, Diagnosed Prevalent Cases of PACG, Men and Women, Ages =40 Years, N, 2020
Figure 27: 7MM, Diagnosed Prevalent Cases of Acute and Chronic PACG, Men and Women, Ages =40 Years, N, 2020
Figure 28: 7MM, Diagnosed Incident Cases of Acute PACG, Men and Women, Ages =40 Years, N, 2020
Figure 29: 7MM, Diagnosed Prevalent Cases of NTG, Men and Women, Ages =40 Years, N, 2020
Figure 30: 7MM, Diagnosed Prevalent Cases of SG, Men and Women, Ages =40 Years, N, 2020
Figure 31: 7MM, Diagnosed Prevalent Cases of PPG, Men and Women, Ages =40 Years, N, 2020
Figure 32: Glaucoma Clinical Treatment Flowchart
Figure 33: Unmet Needs and Opportunities in Glaucoma, 2021
Figure 34: Overview of the Development Pipeline in Glaucoma
Figure 35: Key Late-Stage Trials for the Promising Pipeline Agents that the Analyst Expects to Be Licensed for Glaucoma in the 7MM During the Forecast Period
Figure 36: Competitive Assessment of the Late-Stage Pipeline Agents that the Analyst Expects to Be Licensed for the Treatment of Glaucoma During the Forecast Period
Figure 37: Competitive Assessment of the Pipeline Drugs Benchmarked Against the Standard of Care (SOC), Rhopressa
Figure 38: Analysis of the Company Portfolio Gap in Glaucoma During the Forecast Period
Figure 39: Global (7MM) Sales Forecast by Country for Glaucoma in 2020 and 2030
Figure 40: Sales Forecast by Class for Glaucoma in the US in 2020 and 2030
Figure 41: Sales Forecast by Class for Glaucoma in the 5EU in 2020 and 2030
Figure 42: Sales Forecast by Class for Glaucoma in Japan in 2020 and 2030
Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

  • Pfizer
  • Allergan
  • Alcon
  • Bausch & Lamb
  • Nic0x
  • Mallinckrodt Plc
  • Santen
  • Merck
  • Bruschettini Srl
  • Aerie Pharmaceuticals
  • Otsuka Pharmaceutical
  • Aton
  • Thea Pharma
  • Novatis
  • Kowa Co Ltd
  • Sandoz International
  • OmniVision
  • Eisai Co Ltd
  • Concordia International
  • Teofarma Srl
  • Sanwa Kagaku Kenkyusho
  • Ocular Therapeutix Inc
  • ViSci Ltd
  • Ono Pharmaceutical
  • D. Western Therapeutics
  • Sylentis SAU
  • pH Pharma Co Ltd
Note: Product cover images may vary from those shown